Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Pharmacology and Experimental Therapeutics|May 22, 2009
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock periodKevin M Walton, Katherine Fisher, David Rubitski, et al.
International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.
Cell Metabolism|January 21, 2020
Calcitonin Receptor Neurons in the Mouse Nucleus Tractus Solitarius Control Energy Balance via the Non-aversive Suppression of FeedingWenwen Cheng, Ian Gonzalez, Warren Pan, et al.
BMJ Open|October 11, 2014
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's diseaseBrian Lawlor, Sean Kennelly, Sarah O'Dwyer, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
BMJ Open|July 21, 2016
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flowOlga Meulenbroek, Sarah O'Dwyer, Daan de Jong, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Plos Medicine|September 25, 2018
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trialBrian Lawlor, Ricardo Segurado, Sean Kennelly, et al.
Pageof 6